Integrated virologic analysis of resistance to nirmatrelvir/ritonavir in individuals across four phase 2/3 clinical studies for the treatment of COVID-19Research in context
Summary: Background: SARS-CoV-2 resistance to nirmatrelvir/ritonavir (NMV/r) surveillance is essential to identify emergence and track treatment-resistance. Methods: This integrative virologic analysis across EPIC (Evaluation of Protease Inhibition of COVID-19) phase 2/3 clinical studies (-High Ris...
Saved in:
Main Authors: | Mary Lynn Baniecki, Shunjie Guan, Devendra K. Rai, Qingyi Yang, Jonathan T. Lee, Li Hao, Edward Weinstein, Craig Hyde, Rhonda D. Cardin, Holly Soares, Jennifer Hammond |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-08-01
|
Series: | EBioMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396425002634 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS
by: T. N. Komarov, et al.
Published: (2023-05-01) -
Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022-12-01) -
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2023-01-01) -
Efficacy of Nirmatrelvir tablet/Ritonavir tablet in patients infected with COVID-19 aged 90 years and older
by: WEI Xueman, et al.
Published: (2025-05-01) -
Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: “Symptom Rebound”
by: Ashish Bhargava, et al.
Published: (2025-05-01)